Literature DB >> 10391280

Improved perfusion and contractile reserve after transmyocardial laser revascularization in a model of hibernating myocardium.

G C Hughes1, A P Kypson, J D St Louis, B H Annex, R E Coleman, T R DeGrado, C L Donovan, J E Lowe, K P Landolfo.   

Abstract

BACKGROUND: Transmyocardial laser revascularization (TMR) has been demonstrated effective for relieving angina, although prior studies have yielded inconsistent results regarding postoperative myocardial perfusion and function. This study evaluated long-term changes in myocardial perfusion and contractile reserve after TMR in a model of hibernating myocardium.
METHODS: Miniswine had subtotal left circumflex coronary artery occlusion to reduce resting blood flow to 10% of baseline. After 2 weeks in the low-flow state, positron emission tomography and dobutamine stress echocardiography were performed to document ischemic, viable (hibernating) myocardium in the left circumflex distribution. Animals then had sham redo thoracotomy (n = 4) or TMR (n = 6). Six months later the positron emission tomography and dobutamine stress echocardiography studies were repeated.
RESULTS: Myocardial blood flow in the left circumflex distribution as measured by positron emission tomography was significantly reduced in all animals after 2 weeks in the low-flow state. In animals that had TMR, there was significant improvement in myocardial blood flow to the lased regions 6 months postoperatively. No significant change in myocardial blood flow was seen in sham animals at 6 months. Dobutamine stress echocardiography after 2 weeks of low-flow demonstrated severe hypocontractility at rest in the left circumflex region of all animals, with a biphasic response to dobutamine consistent with hibernating myocardium. In animals that had TMR, there was a trend toward improved resting function and significantly improved regional stress function in the lased segments 6 months postoperatively, consistent with a reduction in ischemia. Global left ventricular wall motion at peak stress improved significantly as well. There was no change in wall motion 6 months postoperatively in sham-operated animals.
CONCLUSIONS: This study found improvements in myocardial perfusion and regional and global contractile reserve 6 months after TMR in a porcine model of hibernating myocardium. This improved perfusion and function likely accounts for the clinical benefits of the procedure.

Entities:  

Mesh:

Year:  1999        PMID: 10391280     DOI: 10.1016/s0003-4975(99)00317-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Percutaneous Myocardial Revascularization.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 2.  Epicardial gene therapy and laser revascularization.

Authors:  J F Symes
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

Review 3.  Transmyocardial laser revascularization.

Authors:  Keith A Horvath
Journal:  J Card Surg       Date:  2008 May-Jun       Impact factor: 1.620

4.  Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.

Authors:  Shao-ping Nie; Xiao Wang; Shi-bin Qiao; Qiu-tang Zeng; Ju-quan Jiang; Xiao-qing Liu; Xiang-ming Zhu; Guo-xiang Cao; Chang-sheng Ma
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

5.  The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-induced benefits?

Authors:  Roberto Bolli; Buddhadeb Dawn
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

Review 6.  Novel revascularization therapies--TMLR and growth factor-induced angiogenesis monitored with cardiac MRI.

Authors:  N M Wilke; A Zenovich; O Muehling; M Jerosch-Herold
Journal:  MAGMA       Date:  2000-11       Impact factor: 2.533

Review 7.  Transmyocardial revascularization devices: technology update.

Authors:  Bogdan A Kindzelski; Yifu Zhou; Keith A Horvath
Journal:  Med Devices (Auckl)       Date:  2014-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.